复方磷酸可待因溶液治疗慢性阻塞性肺疾病急性加重期的疗效观察

目的 观察常规疗法加复方磷酸可待因溶液治疗慢性阻塞性肺疾病（COPD）急性加重期的疗效和安全性。方法 100例COPD急性加重期的患者随机分为两组。治疗组50例，在常规治疗基础上加用复方磷酸可待因溶液10ml，口服，每日三次，连用7天。另有常规治疗组50例，仅用吸氧、抗感染、必嗽平、改善通气等常规处理。结果 治疗组总有效率为96%，与对照组（64%）相比，差别有显著意义（P〈0.05）。两组均未发现严重不良反应。结论 复方磷酸可待因溶液可有效改善COPD急性期患者的症状，是该病有效的辅助治疗药物之一。     

复方磷酸可待因溶液治疗稳定期慢性阻塞性肺病患者的作用评价

目的:探讨复方磷酸可待因溶液(奥亭止咳露)在稳定期慢性阻塞性肺疾病(COPD)中的辅助治疗作用。方法:共研究稳定期COPD患者120例,分3组,其中奥亭组(A组)40例,奥亭+氨溴索组(B组)40例,氨溴索组(C组)40例。各组年龄、症状等一般资料无明显差异,均用药7d。比较治疗前及服药后第4、8天时症状评分,并判定疗效。结果:3组各种症状在第4天均有不同程度的改善,第8天则更明显。治疗后总的症状评分与治疗前比较有明显改善(P<0.001),同时夜间睡眠改善。所有患者均未出现明显不良反应。结论:奥亭止咳露单用或联用氨溴索均可有效改善稳定期COPD患者的症状、改善睡眠质量,是有效辅助治疗药物之一。     

慢性阻塞性肺疾病急性加重期的治疗

慢性阻塞性肺疾病(COPD)是呼吸系统的常见病,致残率和致死率都相当高,COPD死亡率居全世界疾病死亡原因的第四位,在我国农村和城市的疾病死亡原因中分别排第一位和第四位。COPD是一种可预防和治疗的疾病,以气流受限不完全可逆为特征,其病程可分为急性加重期与稳定期。随着自然病     

咳嗽症状对慢性阻塞性肺疾病急性加重期患者心理和睡眠状况影响及干预研究

目的观察咳嗽症状对慢性阻塞性肺疾病急性加重期(acute exacerbation of chronicobstructive pulmonary disease,AECOPD)患者心理情绪和睡眠状况影响及干预的疗效。方法60例确诊为AECOPD的住院患者随机分为观察组和对照组各30例。观察组男23例,女7例,年龄(73±5)岁;对照组男24例,女6例,年龄(74±3)岁。观察组口服复方磷酸可待因溶液,对照组口服复方甘草合剂进行干预治疗。在干预措施实施前后分别应用心理情绪量表(HAD)和睡眠状况量表(SRSS)对两组患者作心理症状和睡眠状况的测评以及咳嗽、痰量、痰液黏稠度和喘息症状的评分比较。结果干预前两组患者的心理症状、睡眠症状和咳嗽、痰量、痰液黏稠度和喘息症状的评估,其差异均无显著性(P>0.05)。干预后观察组的上述评定指标均明显优于对照组(P<0.005)。相关分析表明,咳嗽症状分值与心理症状的A评分D评分和睡眠状况总评分均呈显著性正相关(P<0.001)。结论应用复方磷酸可待因溶液干预治疗,可缓解AECOPD患者咳嗽、咳痰、喘息症状同时还可改善患者的心理症状和睡眠状况。     

慢性阻塞性肺疾病急性加重糖皮质激素的治疗

COPD是一种可预防和治疗的疾病,以气流受限为特征病情呈进行性发展,气流受限不完全可逆,具有较高的发病率和病死率。慢性阻塞性肺疾病急性加重（acuteexacerbationofchronicobstructivepulmonarydisease,AECOPD）作为c0PD疾病病程中的一个事件,是COPD患者就诊及住院的主要原因,对患者及社会造成了庞大经济负担。糖皮质激素在AECOPD治疗中的地位已得到肯定,但仍存在许多争议的地方,如不同途径对于治疗效果的影响、激素使用中最佳剂量及使用时间的选择、不同类型激素治疗效果的差异等,仍需要进一步研究来指导合理使用糖皮质激素。     

慢性阻塞性肺疾病评估测试在急性加重期的研究

目的探讨慢性阻塞性肺疾病评估测试在慢性阻塞性肺疾病急性加重期的应用以及与肺通气功能之间的关系。方法采用COPD评估测试表(中文版)对50例和40例COPD急性加重期及稳定期患者进行评估,明确两者的差异性,同时对50例急性加重期患者进行肺功能检测,明确其评分与FEV1之间的相关性。结果 50例急性加重期患者CAT评分29.24±5.79,显著高于40例稳定期患者评分20.52±4.34,D组患者CAT评分高于B组,FEV1实测值/预计值%低于B组。50例急性加重期患者CAT评分与FEV1实测值/预计值%呈负相关。结论 COPD评估测试对于COPD急性加重期患者的病情评估具有一定价值,临床应用方便。     

布地奈德混悬液对慢性阻塞性肺疾病急性加重期的疗效观察

目的观察布地奈德混悬液（普米克令舒）雾化吸入治疗慢性阻塞性肺疾病急性加重期（AECOPD）的临床疗效与安全性。方法 70例AECOPD的患者随机分为两组,普米克令舒雾化吸入治疗组及全身激素组,对两组的临床症状及肺功能检查进行评价。结果两组都明显改善患者的临床症状及肺功能指标,观察组对血糖的影响更小。结论普米克令舒雾化吸入治疗AECOPD的疗效明显,不良反应少。     

注射用细辛脑治疗慢性阻塞性肺疾病急性加重期的疗效观察

目的 观察注射用细辛脑治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效.方法 将208例AECOPD患者随机分为观察组(106例)和对照组(102例),两组均给予低流量吸氧、平喘、祛痰、抗感染、皮质激素等治疗,观察组在此基础上用注射用细辛脑静脉输注.观察两组治疗前后症状、体征积分及血气分析变化.结果 观察组治疗后症状、体征积分及血气分析与治疗前树照组治疗后比较均有统计学意义(P<0.05),观察组临床总有效率为85.85%,对照组为70.59%,观察组优于对照组(P<0.05).结论 在常规治疗基础上加用注射用细辛脑静脉输注可以有效提高AECOPD患者的临床疗效.     

孟鲁司特治疗慢性阻塞性肺疾病急性加重期的临床疗效观察

目的 观察孟鲁司特治疗慢性阻塞性肺疾病急性加重期的临床疗效.方法 将入选的66例患者随机分为对照组和治疗组.对照组给予常规治疗,治疗组在此基础上加用孟鲁司特,疗程为10d.于治疗后第10天比较两组中血气分析和应用支气管扩张剂后的肺功能测定的相关指标.结果 与对照组相比,治疗10d后的治疗组氧分压明显增高,而二氧化碳分压明显降低,两组相比差异有统计学意义(P＜0.05).而且肺功能测定结果显示1s用力通气容积占肺活量的比值及1s用力通气容积占预计值的百分比也高于对照组,差异有统计学意义(P＜0.05).结论 孟鲁司特可明显改善慢性阻塞性肺疾病急性加重期患者的血气分析和肺功能.     

匹多莫德治疗慢性阻塞性肺疾病急性加重期疗效观察

目的探讨匹多莫德治疗慢性阻塞性肺疾病急性加重期的疗效。方法将50例患者随机分成治疗组（27例）、对照组（23例）。对照组采用常规治疗、治疗组在其基础上加匹多莫德口服,15天为一疗程。结果治疗组经治疗后,痰量及肺部罗音的的减少程度、持续时间均有不同程度改善,两者相比有显著性差异（P〈0.01）。结论匹多莫德可改善慢性阻塞性肺疾病急性期症状,疗效满意。     

乌司他丁治疗慢性阻塞性肺疾病急性加重期的临床疗效

Objective To discuss the effect of ulinastatin on chronic obstructive pulmonary disease with acute exacerbation and part of the mechanism. Methods Seventy-two cases consistent with the diagnostic criteria were randomly divided into ulinastatin statin therapy group and control group (36 cases each group),two groups both received conventional treatment,the treatment group on this basis was added ulinastatin with 200 000 U,intravenous injection, three times a day. Results In the treatment group the total effective rate was 86.11%, significantly better than in the control group 69.44% (P<0.05), its improvement in APACHE Ⅱ score,blood gas analysis and reduction in CRP,TNF-α,IL-8 was superior to the control group. The treatment group was significantly shorter than the control group in mechanical ventilation and ICU stay time (P<0.05). Conclusions Conventional therapy as basis plus ulinastatin has better clinical efficacy,for whose chronic obstructive pulmonary disease with acute exacerbation mechanism may lie in the inhibition of inflammatory mediators and cytokines release, reducing inflammation, relaxing smooth muscle,improving the patient's ventilatory function and blood rheotogy.     

乌司他丁治疗慢性阻塞性肺疾病急性加重期的临床疗效

Objective To discuss the effect of ulinastatin on chronic obstructive pulmonary disease with acute exacerbation and part of the mechanism. Methods Seventy-two cases consistent with the diagnostic criteria were randomly divided into ulinastatin statin therapy group and control group (36 cases each group),two groups both received conventional treatment,the treatment group on this basis was added ulinastatin with 200 000 U,intravenous injection, three times a day. Results In the treatment group the total effective rate was 86.11%, significantly better than in the control group 69.44% (P<0.05), its improvement in APACHE Ⅱ score,blood gas analysis and reduction in CRP,TNF-α,IL-8 was superior to the control group. The treatment group was significantly shorter than the control group in mechanical ventilation and ICU stay time (P<0.05). Conclusions Conventional therapy as basis plus ulinastatin has better clinical efficacy,for whose chronic obstructive pulmonary disease with acute exacerbation mechanism may lie in the inhibition of inflammatory mediators and cytokines release, reducing inflammation, relaxing smooth muscle,improving the patient's ventilatory function and blood rheotogy.     

乌司他丁治疗慢性阻塞性肺疾病急性加重期的临床疗效

Objective To discuss the effect of ulinastatin on chronic obstructive pulmonary disease with acute exacerbation and part of the mechanism. Methods Seventy-two cases consistent with the diagnostic criteria were randomly divided into ulinastatin statin therapy group and control group (36 cases each group),two groups both received conventional treatment,the treatment group on this basis was added ulinastatin with 200 000 U,intravenous injection, three times a day. Results In the treatment group the total effective rate was 86.11%, significantly better than in the control group 69.44% (P<0.05), its improvement in APACHE Ⅱ score,blood gas analysis and reduction in CRP,TNF-α,IL-8 was superior to the control group. The treatment group was significantly shorter than the control group in mechanical ventilation and ICU stay time (P<0.05). Conclusions Conventional therapy as basis plus ulinastatin has better clinical efficacy,for whose chronic obstructive pulmonary disease with acute exacerbation mechanism may lie in the inhibition of inflammatory mediators and cytokines release, reducing inflammation, relaxing smooth muscle,improving the patient's ventilatory function and blood rheotogy.     

乌司他丁治疗慢性阻塞性肺疾病急性加重期的临床疗效

Objective To discuss the effect of ulinastatin on chronic obstructive pulmonary disease with acute exacerbation and part of the mechanism. Methods Seventy-two cases consistent with the diagnostic criteria were randomly divided into ulinastatin statin therapy group and control group (36 cases each group),two groups both received conventional treatment,the treatment group on this basis was added ulinastatin with 200 000 U,intravenous injection, three times a day. Results In the treatment group the total effective rate was 86.11%, significantly better than in the control group 69.44% (P<0.05), its improvement in APACHE Ⅱ score,blood gas analysis and reduction in CRP,TNF-α,IL-8 was superior to the control group. The treatment group was significantly shorter than the control group in mechanical ventilation and ICU stay time (P<0.05). Conclusions Conventional therapy as basis plus ulinastatin has better clinical efficacy,for whose chronic obstructive pulmonary disease with acute exacerbation mechanism may lie in the inhibition of inflammatory mediators and cytokines release, reducing inflammation, relaxing smooth muscle,improving the patient's ventilatory function and blood rheotogy.     

乌司他丁治疗慢性阻塞性肺疾病急性加重期的临床疗效

Objective To discuss the effect of ulinastatin on chronic obstructive pulmonary disease with acute exacerbation and part of the mechanism. Methods Seventy-two cases consistent with the diagnostic criteria were randomly divided into ulinastatin statin therapy group and control group (36 cases each group),two groups both received conventional treatment,the treatment group on this basis was added ulinastatin with 200 000 U,intravenous injection, three times a day. Results In the treatment group the total effective rate was 86.11%, significantly better than in the control group 69.44% (P<0.05), its improvement in APACHE Ⅱ score,blood gas analysis and reduction in CRP,TNF-α,IL-8 was superior to the control group. The treatment group was significantly shorter than the control group in mechanical ventilation and ICU stay time (P<0.05). Conclusions Conventional therapy as basis plus ulinastatin has better clinical efficacy,for whose chronic obstructive pulmonary disease with acute exacerbation mechanism may lie in the inhibition of inflammatory mediators and cytokines release, reducing inflammation, relaxing smooth muscle,improving the patient's ventilatory function and blood rheotogy.     

乌司他丁治疗慢性阻塞性肺疾病急性加重期的临床疗效

Objective To discuss the effect of ulinastatin on chronic obstructive pulmonary disease with acute exacerbation and part of the mechanism. Methods Seventy-two cases consistent with the diagnostic criteria were randomly divided into ulinastatin statin therapy group and control group (36 cases each group),two groups both received conventional treatment,the treatment group on this basis was added ulinastatin with 200 000 U,intravenous injection, three times a day. Results In the treatment group the total effective rate was 86.11%, significantly better than in the control group 69.44% (P<0.05), its improvement in APACHE Ⅱ score,blood gas analysis and reduction in CRP,TNF-α,IL-8 was superior to the control group. The treatment group was significantly shorter than the control group in mechanical ventilation and ICU stay time (P<0.05). Conclusions Conventional therapy as basis plus ulinastatin has better clinical efficacy,for whose chronic obstructive pulmonary disease with acute exacerbation mechanism may lie in the inhibition of inflammatory mediators and cytokines release, reducing inflammation, relaxing smooth muscle,improving the patient's ventilatory function and blood rheotogy.